Clenbuterol 40 - Adelphi Research

Released as a selective beta-2 agonist, clenbuterol hydrochloride carved a niche in the respiratory drug market by providing long-lasting bronchodilation without strong cardiac stimulation. It was adopted in various countries as a frontline treatment for asthma but was excluded from U.S. pharmaceutical distribution, largely due to lack of demand rather than medical controversy. Its thermogenic and anti-catabolic effects later attracted attention in physique sports and off-label enhancement practices.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Clenbuterol 40 by Adelphi Research, consult with your doctor or healthcare professional.